Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2012

Open Access 01-02-2012 | Research article

Tumor necrosis factor α release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients

Authors: Adam S Nabatian, Muhammad M Bashir, Maria Wysocka, Meena Sharma, Victoria P Werth

Published in: Arthritis Research & Therapy | Issue 1/2012

Login to get access

Abstract

Introduction

Several studies have reported that TNFα is substantially increased within skin lesions of patients with discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE) and dermatomyositis (DM) compared to controls. Elevated TNFα has been reported in the sera of some patients with systemic lupus erythematosus, DLE and SCLE, but not in the sera of patients with DM. Because of the key pathogenic role of autoimmunity in these diseases, in this study we sought to evaluate TNFα production by a readily available source of immune cells (namely, peripheral blood mononuclear cells (PBMCs)) taken from controls and from patients with cutaneous lupus or DM.

Methods

Freshly isolated PBMCs were cultured overnight, and TNFα protein accumulation in conditioned medium was determined. In addition, flow cytometry using cell-type-specific markers was performed to determine the sources of TNFα. One-way analysis of variance and Dunnett's multiple comparisons test were performed for statistical comparisons.

Results

Accumulation of TNFα protein in conditioned medium containing PBMCs from DLE patients, but not from SCLE, TLE or DM patients, was significantly greater (19-fold) than that from controls (P < 0.001). In DLE PBMCs, increased TNFα was produced by circulating monocytes and myeloid dendritic cells (mDCs). The mean TNFα fluorescence intensity, but not the total number, of both monocytes and mDCs (P < 0.01) from DLE patients was significantly greater (2.3-fold) than that of controls. There were significantly more (13.3-fold) mDCs with intracellular TNFα in blood from DLE patients (P < 0.001) and DM patients (P < 0.001) compared to controls. Most importantly, a positive correlation was seen in DLE patients between their disease activity measured using the Cutaneous Lupus Erythematosus Disease Area and Severity Index and TNFα protein secretion (r = 0.61, P < 0.08).

Conclusions

TNFα protein production by PBMCs is greater in DLE patients than in patients with other cutaneous forms of lupus and DM or in controls. Flow cytometric studies demonstrated that circulating monocytes and mDCs contributed to this increased TNFα production. Monocytes and mDCs are present in lesional skin, and the increased TNFα production by these cells and other PBMCs likely increase the number of inflammatory cells seen in DLE skin relative to other subsets of cutaneous lupus erythematosus and DM. These results provide a possible biological explanation for the denser infiltrate seen in DLE relative to DM.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fabbri P, Cardinali C, Giomi B, Caproni M: Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol. 2003, 4: 449-465. 10.2165/00128071-200304070-00002.CrossRefPubMed Fabbri P, Cardinali C, Giomi B, Caproni M: Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol. 2003, 4: 449-465. 10.2165/00128071-200304070-00002.CrossRefPubMed
2.
go back to reference Gilliam JN, Sontheimer RD: Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981, 4: 471-475. 10.1016/S0190-9622(81)80261-7.CrossRefPubMed Gilliam JN, Sontheimer RD: Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981, 4: 471-475. 10.1016/S0190-9622(81)80261-7.CrossRefPubMed
3.
go back to reference Sontheimer RD: The lexicon of cutaneous lupus erythematosus: a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Lupus. 1997, 6: 84-95. 10.1177/096120339700600203.CrossRefPubMed Sontheimer RD: The lexicon of cutaneous lupus erythematosus: a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Lupus. 1997, 6: 84-95. 10.1177/096120339700600203.CrossRefPubMed
4.
go back to reference Lin JH, Dutz JP, Sontheimer RD, Werth VP: Pathophysiology of cutaneous lupus erythematosus. Clin Rev Allergy Immunol. 2007, 33: 85-106. 10.1007/s12016-007-0031-x.CrossRefPubMed Lin JH, Dutz JP, Sontheimer RD, Werth VP: Pathophysiology of cutaneous lupus erythematosus. Clin Rev Allergy Immunol. 2007, 33: 85-106. 10.1007/s12016-007-0031-x.CrossRefPubMed
5.
go back to reference Caproni M, Torchia D, Cardinali C, Volpi W, Del Bianco E, D'Agata A, Fabbri P: Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis. Br J Dermatol. 2004, 151: 784-791. 10.1111/j.1365-2133.2004.06144.x. [see comment]CrossRefPubMed Caproni M, Torchia D, Cardinali C, Volpi W, Del Bianco E, D'Agata A, Fabbri P: Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis. Br J Dermatol. 2004, 151: 784-791. 10.1111/j.1365-2133.2004.06144.x. [see comment]CrossRefPubMed
6.
go back to reference Smith ES, Hallman JR, DeLuca AM, Goldenberg G, Jorizzo JL, Sangueza OP: Dermatomyositis: a clinicopathological study of 40 patients. Am J Dermatopathol. 2009, 31: 61-67. 10.1097/DAD.0b013e31818520e1.CrossRefPubMed Smith ES, Hallman JR, DeLuca AM, Goldenberg G, Jorizzo JL, Sangueza OP: Dermatomyositis: a clinicopathological study of 40 patients. Am J Dermatopathol. 2009, 31: 61-67. 10.1097/DAD.0b013e31818520e1.CrossRefPubMed
7.
8.
go back to reference Schäkel K, Kannagi R, Kniep B, Goto Y, Mitsuoka C, Zwirner J, Soruri A, von Kietzell M, Rieber E: 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity. 2002, 17: 289-301. 10.1016/S1074-7613(02)00393-X.CrossRefPubMed Schäkel K, Kannagi R, Kniep B, Goto Y, Mitsuoka C, Zwirner J, Soruri A, von Kietzell M, Rieber E: 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity. 2002, 17: 289-301. 10.1016/S1074-7613(02)00393-X.CrossRefPubMed
9.
go back to reference Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, Nussbaum R, Novitskaya I, Carbonaro H, Cardinale I, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Wittkowski KM, Papp K, Garovoy M, Dummer W, Steinman RM, Krueger JG: Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA. 2005, 102: 19057-19062. 10.1073/pnas.0509736102.PubMedCentralCrossRefPubMed Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, Nussbaum R, Novitskaya I, Carbonaro H, Cardinale I, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Wittkowski KM, Papp K, Garovoy M, Dummer W, Steinman RM, Krueger JG: Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA. 2005, 102: 19057-19062. 10.1073/pnas.0509736102.PubMedCentralCrossRefPubMed
10.
go back to reference Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP: A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature. 1997, 385: 729-733. 10.1038/385729a0.CrossRefPubMed Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP: A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature. 1997, 385: 729-733. 10.1038/385729a0.CrossRefPubMed
11.
go back to reference Kawaguchi M, Mitsuhashi Y, Kondo S: Overexpression of tumour necrosis factor-α-converting enzyme in psoriasis. Br J Dermatol. 2005, 152: 915-919. 10.1111/j.1365-2133.2005.06440.x.CrossRefPubMed Kawaguchi M, Mitsuhashi Y, Kondo S: Overexpression of tumour necrosis factor-α-converting enzyme in psoriasis. Br J Dermatol. 2005, 152: 915-919. 10.1111/j.1365-2133.2005.06440.x.CrossRefPubMed
12.
go back to reference Toro JR, Finlay D, Dou X, Zheng SC, LeBoit PE, Connolly MK: Detection of type 1 cytokines in discoid lupus erythematosus. Arch Dermatol. 2000, 136: 1497-1501. 10.1001/archderm.136.12.1497.PubMed Toro JR, Finlay D, Dou X, Zheng SC, LeBoit PE, Connolly MK: Detection of type 1 cytokines in discoid lupus erythematosus. Arch Dermatol. 2000, 136: 1497-1501. 10.1001/archderm.136.12.1497.PubMed
13.
go back to reference Popovic K, Ek M, Espinosa A, Padyukov L, Harris HE, Wahren-Herlenius M, Nyberg F: Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erthematosus. Arthr Rheum. 2005, 52: 3639-3645. 10.1002/art.21398.CrossRef Popovic K, Ek M, Espinosa A, Padyukov L, Harris HE, Wahren-Herlenius M, Nyberg F: Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erthematosus. Arthr Rheum. 2005, 52: 3639-3645. 10.1002/art.21398.CrossRef
14.
go back to reference Drosera M, Facchetti F, Landolfo S, Mondini M, Nyberg F, Parodi A, Santoro A, Zampieri S, Doria A: Role of soluble and cell surface molecules in the pathogenesis of autoimmune skin diseases. Clin Exp Rheumatol. 2006, 24 (1 Suppl 40): S7-S13.PubMed Drosera M, Facchetti F, Landolfo S, Mondini M, Nyberg F, Parodi A, Santoro A, Zampieri S, Doria A: Role of soluble and cell surface molecules in the pathogenesis of autoimmune skin diseases. Clin Exp Rheumatol. 2006, 24 (1 Suppl 40): S7-S13.PubMed
15.
go back to reference Zampieri S, Alaibac M, Laccarino L, Rondinone R, Ghirardello A, Sarzi-Puttini P, Doria A, Peserico A: TNF α is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. Ann Rheum Dis. 2006, 65: 545-548. 10.1136/ard.2005.039362.PubMedCentralCrossRefPubMed Zampieri S, Alaibac M, Laccarino L, Rondinone R, Ghirardello A, Sarzi-Puttini P, Doria A, Peserico A: TNF α is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. Ann Rheum Dis. 2006, 65: 545-548. 10.1136/ard.2005.039362.PubMedCentralCrossRefPubMed
16.
go back to reference De Bleecker JL, Meire VI, Declercq W, Van Aken EH: Immunolocalization of tumor necrosis factor-α and its receptors in inflammatory myopathies. Neuromuscul Disord. 1999, 9: 239-246. 10.1016/S0960-8966(98)00126-6.CrossRefPubMed De Bleecker JL, Meire VI, Declercq W, Van Aken EH: Immunolocalization of tumor necrosis factor-α and its receptors in inflammatory myopathies. Neuromuscul Disord. 1999, 9: 239-246. 10.1016/S0960-8966(98)00126-6.CrossRefPubMed
17.
go back to reference Alecu M, Coman G, Alecu S: Serological levels of apoptotic bodies, sFAS and TNF in lupus erythematosus. Rom J Intern Med. 2001, 38-39: 83-88. Alecu M, Coman G, Alecu S: Serological levels of apoptotic bodies, sFAS and TNF in lupus erythematosus. Rom J Intern Med. 2001, 38-39: 83-88.
18.
go back to reference Sabry A, Sheashaa H, El-Husseini A, Mahmoud K, Eldahshan KF, George SK, Abdel-Khalek E, El-Shafey EM, Abo-Zenah H: Proinflammatory cytokines (TNF-α and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine. 2006, 35: 148-153. 10.1016/j.cyto.2006.07.023.CrossRefPubMed Sabry A, Sheashaa H, El-Husseini A, Mahmoud K, Eldahshan KF, George SK, Abdel-Khalek E, El-Shafey EM, Abo-Zenah H: Proinflammatory cytokines (TNF-α and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine. 2006, 35: 148-153. 10.1016/j.cyto.2006.07.023.CrossRefPubMed
19.
go back to reference Maczynska I, Millo B, Ratajczak-Stefańska V, Maleszka R, Szych Z, Kurpisz M, Giedrys-Kalemba S: Proinflammatory cytokine (IL-1β, IL-6, IL-12, IL-18 and TNF-α) levels in sera of patients with subacute cutaneous lupus erythematosus (SCLE). Immunol Lett. 2006, 102: 79-82. 10.1016/j.imlet.2005.08.001.CrossRefPubMed Maczynska I, Millo B, Ratajczak-Stefańska V, Maleszka R, Szych Z, Kurpisz M, Giedrys-Kalemba S: Proinflammatory cytokine (IL-1β, IL-6, IL-12, IL-18 and TNF-α) levels in sera of patients with subacute cutaneous lupus erythematosus (SCLE). Immunol Lett. 2006, 102: 79-82. 10.1016/j.imlet.2005.08.001.CrossRefPubMed
20.
go back to reference Shimizu T, Tomita Y, Son K, Nishinarita S, Sawada S, Horie T: Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin Rheum. 2000, 19: 352-359. 10.1007/s100670070027.CrossRef Shimizu T, Tomita Y, Son K, Nishinarita S, Sawada S, Horie T: Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin Rheum. 2000, 19: 352-359. 10.1007/s100670070027.CrossRef
21.
go back to reference Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM, Chen EH: TNFα-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor α, disease duration, and pathologic calcifications. Arthritis Rheum. 2000, 43: 2368-2377. 10.1002/1529-0131(200010)43:10<2368::AID-ANR26>3.0.CO;2-8.CrossRefPubMed Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM, Chen EH: TNFα-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor α, disease duration, and pathologic calcifications. Arthritis Rheum. 2000, 43: 2368-2377. 10.1002/1529-0131(200010)43:10<2368::AID-ANR26>3.0.CO;2-8.CrossRefPubMed
22.
go back to reference Krathen M, Albrecht J, Werth VP: The cutaneous lupus disease activity and severity index as a validated outcome measure for cutaneous lupus erythematosus: comment on the article by Stamm et al. Arthritis Rheum. 2008, 59: 601-602. Comment on Arthritis Rheum 2007, 57:1287-1295PubMedCentralCrossRefPubMed Krathen M, Albrecht J, Werth VP: The cutaneous lupus disease activity and severity index as a validated outcome measure for cutaneous lupus erythematosus: comment on the article by Stamm et al. Arthritis Rheum. 2008, 59: 601-602. Comment on Arthritis Rheum 2007, 57:1287-1295PubMedCentralCrossRefPubMed
23.
go back to reference Yassaee M, Fiorentino D, Okawa J, Taylor L, Coley C, Troxel AB, Werth VP: Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument. Br J Dermatol. 2010, 162: 669-673. 10.1111/j.1365-2133.2009.09521.x.PubMedCentralCrossRefPubMed Yassaee M, Fiorentino D, Okawa J, Taylor L, Coley C, Troxel AB, Werth VP: Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument. Br J Dermatol. 2010, 162: 669-673. 10.1111/j.1365-2133.2009.09521.x.PubMedCentralCrossRefPubMed
24.
go back to reference Pober JS, Bevilacqua MP, Mendrick DL, Lapierre LA, Fiers W, Gimbrone MA: Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol. 1986, 136: 1680-1687.PubMed Pober JS, Bevilacqua MP, Mendrick DL, Lapierre LA, Fiers W, Gimbrone MA: Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol. 1986, 136: 1680-1687.PubMed
25.
go back to reference Munro JM, Pober JS, Cotran RS: Tumor necrosis factor and interferon-γ induce distinct patterns of endothelial activation and associated leukocyte accumulation in skin of Papio anubis. Am J Pathol. 1989, 135: 121-133.PubMedCentralPubMed Munro JM, Pober JS, Cotran RS: Tumor necrosis factor and interferon-γ induce distinct patterns of endothelial activation and associated leukocyte accumulation in skin of Papio anubis. Am J Pathol. 1989, 135: 121-133.PubMedCentralPubMed
26.
go back to reference Swerlick RA, Lee KH, Li KJ, Sepp NT, Caughman SW, Lawley TJ: Regulation of vascular cell adhesion molecule 1 on human dermal microvascular endothelial cells. J Immunol. 1992, 149: 698-705.PubMed Swerlick RA, Lee KH, Li KJ, Sepp NT, Caughman SW, Lawley TJ: Regulation of vascular cell adhesion molecule 1 on human dermal microvascular endothelial cells. J Immunol. 1992, 149: 698-705.PubMed
27.
go back to reference Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J: Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science. 2001, 294: 1540-1543. 10.1126/science.1064890.CrossRefPubMed Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J: Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science. 2001, 294: 1540-1543. 10.1126/science.1064890.CrossRefPubMed
28.
go back to reference Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T: Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol. 1987, 70: 562-569.PubMedCentralPubMed Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T: Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol. 1987, 70: 562-569.PubMedCentralPubMed
29.
go back to reference Johnson-Huang LM, McNutt NS, Krueger JG, Lowes MA: Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol. 2009, 29: 247-256. 10.1007/s10875-009-9278-8.PubMedCentralCrossRefPubMed Johnson-Huang LM, McNutt NS, Krueger JG, Lowes MA: Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol. 2009, 29: 247-256. 10.1007/s10875-009-9278-8.PubMedCentralCrossRefPubMed
30.
go back to reference Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL: Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol. 2001, 159: 237-243. 10.1016/S0002-9440(10)61689-6.PubMedCentralCrossRefPubMed Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL: Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol. 2001, 159: 237-243. 10.1016/S0002-9440(10)61689-6.PubMedCentralCrossRefPubMed
31.
go back to reference Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, Pierson KC, Gonzalez J, Krueger JG, Lowes MA: Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol. 2009, 129: 79-88. 10.1038/jid.2008.194.PubMedCentralCrossRefPubMed Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, Pierson KC, Gonzalez J, Krueger JG, Lowes MA: Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol. 2009, 129: 79-88. 10.1038/jid.2008.194.PubMedCentralCrossRefPubMed
32.
go back to reference Guilliams M, Movahedi K, Bosschaerts T, VandenDriessche T, Chuah MK, Hérin M, Acosta-Sanchez A, Ma L, Moser M, Van Ginderachter JA, Van Ginderachter JA, Brys L, De Baetselier P, Beschin A: IL-10 dampens TNF/inducible nitric oxide synthase-producing dendritic cell-mediated pathogenicity during parasitic infection. J Immunol. 2009, 182: 1107-1118.CrossRefPubMed Guilliams M, Movahedi K, Bosschaerts T, VandenDriessche T, Chuah MK, Hérin M, Acosta-Sanchez A, Ma L, Moser M, Van Ginderachter JA, Van Ginderachter JA, Brys L, De Baetselier P, Beschin A: IL-10 dampens TNF/inducible nitric oxide synthase-producing dendritic cell-mediated pathogenicity during parasitic infection. J Immunol. 2009, 182: 1107-1118.CrossRefPubMed
33.
go back to reference Schäkel K, Poppe C, Mayer E, Federle C, Riethmüller G, Rieber EP: M-DC8+ leukocytes: a novel human dendritic cell population. Pathobiology. 1999, 67: 287-290. 10.1159/000028081.CrossRefPubMed Schäkel K, Poppe C, Mayer E, Federle C, Riethmüller G, Rieber EP: M-DC8+ leukocytes: a novel human dendritic cell population. Pathobiology. 1999, 67: 287-290. 10.1159/000028081.CrossRefPubMed
34.
go back to reference de Baey A, Mende I, Riethmueller G, Baeuerle PA: Phenotype and function of human dendritic cells derived from M-DC8+ monocytes. Eur J Immunol. 2001, 31: 1646-1655. 10.1002/1521-4141(200106)31:6<1646::AID-IMMU1646>3.0.CO;2-X.CrossRefPubMed de Baey A, Mende I, Riethmueller G, Baeuerle PA: Phenotype and function of human dendritic cells derived from M-DC8+ monocytes. Eur J Immunol. 2001, 31: 1646-1655. 10.1002/1521-4141(200106)31:6<1646::AID-IMMU1646>3.0.CO;2-X.CrossRefPubMed
35.
go back to reference de Baey A, Mende I, Baretton G, Greiner A, Hartl WH, Baeuerle PA, Diepolder HM: A subset of human dendritic cells in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-α. J Immunol. 2003, 170: 5089-5094.CrossRefPubMed de Baey A, Mende I, Baretton G, Greiner A, Hartl WH, Baeuerle PA, Diepolder HM: A subset of human dendritic cells in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-α. J Immunol. 2003, 170: 5089-5094.CrossRefPubMed
Metadata
Title
Tumor necrosis factor α release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients
Authors
Adam S Nabatian
Muhammad M Bashir
Maria Wysocka
Meena Sharma
Victoria P Werth
Publication date
01-02-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3549

Other articles of this Issue 1/2012

Arthritis Research & Therapy 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.